- Home
- MOS vs HALO Comparison
MOS vs HALO Comparison
Compare MOS & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOS | HALO |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.4B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | MOS | HALO |
|---|---|---|
| Price | $26.54 | $72.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | $34.50 | ★ $74.62 |
| AVG Volume (30 Days) | ★ 7.5M | 2.3M |
| Earning Date | 02-26-2026 | 02-17-2026 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | ★ 235.95 | 56.68 |
| EPS | 3.87 | ★ 4.74 |
| Revenue | ★ $11,894,600,000.00 | $1,242,852,000.00 |
| Revenue This Year | $13.02 | $34.83 |
| Revenue Next Year | $2.54 | $24.84 |
| P/E Ratio | ★ $6.85 | $15.23 |
| Revenue Growth | 3.83 | ★ 31.19 |
| 52 Week Low | $22.36 | $47.50 |
| 52 Week High | $38.23 | $79.50 |
Technical Indicators
Market Signals| Indicator | MOS | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 64.54 | 63.11 |
| Support Level | $24.69 | $67.02 |
| Resistance Level | $25.42 | $75.59 |
| Average True Range (ATR) | 0.64 | 1.95 |
| MACD | 0.30 | 0.86 |
| Stochastic Oscillator | 89.74 | 74.25 |
Price Performance
Historical ComparisonAbout MOS Mosaic Company (The)
Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida and Peru and potash mines in Saskatchewan and New Mexico. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.